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CUH or from subsequent contact with unsuspected carriers 
in the case-patient’s family or the community. On the basis 
of a matching surname, case-patient E was determined to be 
a member of the same family as case-patients P20, P26, and 
likely C. Soft tissue infection was documented in all 5 case-
patients, supporting the original observation that ST2371 is 
associated with disease. Evidence of familial transmission 
in the original outbreak is further supported by transmission 
between case-patients P20, P26, C, and E. Furthermore, 2 
case-patients infected during the original outbreak, P22/A 
and P14/B, continued to experience disease signs and symp-
toms for >15 months after their initial diagnosis.
Our data highlight the role of hospitals as reservoirs of 
MRSA and subsequent failure to track the entry and spread 
of MRSA in the community. MRSA decolonization was 
advised in all cases in the original outbreak, but this pro-
cess clearly proved ineffective for case-patients A and B. 
Potential explanations include not implementing or com-
pleting the course of decolonization; failed decolonization; 
or limiting decolonization to only some members of an af-
fected family. Although the outbreak in the hospital ward 
was resolved, the lack of a systematic surveillance program 
to monitor the incidence of noninvasive MRSA infections 
among the case-patients’ contacts and the community al-
lowed this novel lineage to continue to cause disease in a 
group of linked persons. Considering recommendations to 
move from universal to targeted MRSA screening in hospi-
tals in England (6), more active surveillance of any identi-
fied case-patients or carriers of MRSA in the community 
may be warranted.
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To the Editor: In Queensland, Australia, a steady in-
crease in community-acquired (CA) Clostridium difficile 
infections (CDI) during 2003–2012 could not be explained 
by patients’ demographic characteristics or environmental 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 9, September 2016 1659
LETTERS
factors (1). Several risk factors have been implicated in 
the increased rates of CA-CDI, primarily exposure to an-
timicrobial drugs, gastric acid–suppression drugs, and 
corticosteroids (2). Given the recent rise in prescription of 
corticosteroids and proton pump inhibitors in Australia, we 
hypothesized that the observed increase in CA-CDI was as-
sociated with increased drug prescriptions.
To test our hypothesis, we analyzed a subset of data 
used in a previous study (1), which included fecal samples 
from patients seen by general practitioners in the com-
munity from January 2008 through December 2012. The 
samples were submitted to Sullivan Nicolaides Pathology 
(Taringa, Queensland, Australia) for C. difficile toxin gene 
detection. After samples submitted from healthcare facili-
ties and nursing homes were excluded, the final dataset 
contained data from 14,330 fecal samples. We aggregated 
the data by patient sex, age categories, year, and statistical 
area level 4 (SA4). For each sex-age-year-SA4 group, we 
used as numerators the numbers of CA-CDI cases identi-
fied and as denominators the numbers of samples submitted 
for microbiological testing. 
The Australian Department of Human Services pro-
vided data from the Pharmaceutical Benefits Scheme. The 
quantities of 11 anatomic therapeutic chemical drugs were 
accessed by patient sex, age group, year, and SA4. Cor-
responding with the CA-CDI data, medication data to be 
analyzed were then aggregated by sex, age group, year, 
and SA4.
For each medication, we built binomial logistic re-
gression models, using CA-CDI status as the outcome, in 
a Bayesian framework, incorporating fixed effects for sex, 
age group, quantity of drug prescribed, year (2008–2012), 
and spatially unstructured random effects at the SA4 level. 
After performing an initial burn-in, we stored and summa-
rized 1,000 values from the posterior distribution of each 
parameter by using descriptive statistics (posterior mean, 
95% posterior credible interval [95% CrI], and p value). 
We examined multiple pairwise comparisons of CA-CDI 
and medication exposure; thus, we used the Holm adjust-
ment for p values to avoid  inflation and to control the fami-
lywise error rate.
Of the 14,330 fecal samples tested, 1,430 (10%) were 
positive for C. difficile. The proportion of positive fecal 
samples increased over the 5-year period, from 7.10% in 
2008 to 12.72% in 2011 and 11.48% in 2012 (p<0.001). 
After adjusting the regression models for sex, age group, 
temporal pattern, and spatial distribution, we found that ex-
posure to antimycobacterial drugs (odds ratio [OR] 1.09; 
95% CrI 1.02–1.16) and anthelmintic drugs (OR 1.07; 
95% CrI 1.01–1.13) were associated with increased odds 
of CA-CDI. After post hoc Holm adjustments, no statisti-
cally significant association between medication exposure 
and CA-CDI was observed (Table).
Our findings suggest that the increase in CA-CDI pro-
portion was not associated with population-level medica-
tion exposure in Queensland during 2008–2012. CA-CDI 
epidemiology in Queensland might be driven by a group of 
factors other than medication exposure, such as transmis-
sion of the pathogen from food, animals, or hospitals into 
the community. Studies have confirmed the risk for food-
borne and animalborne spread of C. difficile into the com-
munity (3). In Australia and New Zealand, importation of 
onions and garlic from the United States and Mexico might 
be responsible for increased CDI cases during Southern 
Hemisphere summers (4), and high prevalence of C. dif-
ficile colonization in piglets has been identified (5). How-
ever, the role of these factors in leading to CA-CDI cases 
remains unknown.
A recent contact tracing study in the United King-
dom demonstrated that a considerable proportion of CDIs 
among patients in healthcare settings originated from the 
community (6); this finding was supported by another 
study, which showed that in Queensland, more than two 
thirds of patients with CA-CDI required hospitalization 
(7). Currently, there is no evidence of a reverse-infection 
route (healthcare-acquired CDI being transmitted to per-
sons in the community). However, Sethi et al. documented 
environmental shedding of C. difficile by inpatients for 
several weeks after resolution of symptoms (8). There-
fore, the possibility that asymptomatic patients might be 
a source of transmission after hospital discharge needs 
to be examined. In recent years, epidemiologic models 
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Table. Binomial logistic regression models for medication exposure adjusted for sex, age group, temporal pattern, and spatial 
distribution among patients with community-acquired Clostridium difficile infection, Queensland, Australia, 2003–2012 
Medication exposure Odds ratio (95% credible interval) p value Holm-adjusted p value 
Drugs for acid-related disorders 1.052 (0.943–1.163) 0.348 0.819 
Drugs for constipation 1.056 (0.963–1.151) 0.235 0.781 
Antidiarrheal drugs 1.106 (0.994–1.218) 0.051 0.379 
Antithrombotic drugs 1.073 (0.955–1.197) 0.224 0.781 
Corticosteroids for systemic use 1.043 (0.952–1.133) 0.348 0.819 
Antibacterial drugs for systemic use 1.083 (0.990–1.174) 0.067 0.425 
Antimycotic drugs for systemic use 1.035 (0.944–1.126) 0.454 0.819 
Antimicrobial drugs for mycobacterial infections  1.089 (1.023–1.155) 0.006 0.063 
Anti-inflammatory drugs 1.070 (0.970–1.170) 0.158 0.700 
Antiprotozoal drugs 1.037 (0.953–1.123) 0.394 0.819 
Anthelminthic drugs 1.068 (1.008–1.127) 0.021 0.189 
             
exploring the role of CDI coming from the community into 
the hospital have become increasingly popular (9); how-
ever, to the best of our knowledge, only 1 modeling study 
described CDI dynamics within the wider community 
(10). Although this approach is innovative, we acknowl-
edge some limitations. Medication exposure was used as a 
proxy, based on the average prescription in the community, 
and it cannot be applied to the individual patient. In addi-
tion, we were unable to adjust the regression model for 
the presence of concurrent medical conditions and other 
unmeasured confounders.
Exposure to medications, particularly antimicrobial 
drugs, probably influences CA-CDI pathogenesis (2). How-
ever, our community-based assessment indicates that a more 
holistic exploration is needed to identify alternative factors 
driving increases in CA-CDI cases in the wider population.
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To the Editor: In 2015, an outbreak of multidrug- 
resistant Campylobacter coli was documented in Montreal, 
Quebec, Canada. We report results of an epidemiologic 
and molecular investigation suggesting a sexually trans-
mitted enteric infection among men who have sex with 
men (MSM).
The ethics committee of Centre Hospitalier de 
l’Université de Montréal approved the research. During 
January 14–February 7, 2015, six men 35–62 years of age 
were documented with an enteric, erythromycin-, tetracy-
cline- and ciprofloxacin-resistant C. coli pulsovar 15 infec-
tion. All 6 men had diarrhea; 5 had abdominal pain; 1 had 
fever >39°C; 1 had blood in feces; and 1 had vomiting. No 
extraintestinal focus was documented in these patients. 
Five men were evaluated in the outpatient clinic or 
emergency department; 1 man was hospitalized for 3 days. 
Five patients were treated with an antimicrobial agent. 
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